Louisiana will pay a flat fee for unlimited access to very expensive hepatitis C medication for five years, and will be able to treat as many people as it can, rather than pay a per-patient drug price. The deal allows the state to potentially eradicate the disease in a short time while maintaining a stable budget by spreading the cost over several years.
from Kaiser Health News https://ift.tt/2FBubt3
June 27, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Fiscal general de California: los jueces deben ver que ACA es “indispensable”Sacramento.- Cuando la Corte Suprema de los Estados Unidos esté escuchando el martes 10 un caso que podría decidir el destino de la Ley de Cuidado de Salud a Bajo Precio (ACA), California liderará la defensa de la ley federal… Read More
Cinco preguntas críticas sobre la vacuna contra COVID-19 de PfizerEl anuncio de Pfizer de que su vacuna contra COVID-19 prevendría que nueve de cada 10 personas contraigan la enfermedad hizo que el precio de sus acciones se disparara. Muchos titulares describieron a la vacuna como si fuera … Read More
Biden Plan to Lower Medicare Eligibility Age to 60 Faces Hostility From HospitalsOf his many plans to expand insurance coverage, President-elect Joe Biden’s simplest strategy is lowering the eligibility age for Medicare from 65 to 60. But the plan is sure to face long odds, even if the Democrats can snag … Read More
Five Important Questions About Pfizer’s COVID-19 VaccinePfizer’s announcement on Monday that its COVID-19 shot appears to keep nine in 10 people from getting the disease sent its stock price rocketing. Many news reports described the vaccine as if it were our deliverance from the … Read More
California Stands to Lose Big if US Supreme Court Cancels ObamacareSACRAMENTO, Calif. — Of any state, California has the most to lose if the U.S. Supreme Court overturns the Affordable Care Act. Health care coverage for millions of people is at stake, as are billions in federal dollars. Yet … Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment